Literature DB >> 10881972

Deinstitutionalisation for long-term mental illness: a 2-year clinical evaluation.

C Hobbs1, C Tennant, A Rosen, L Newton, H M Lapsley, K Tribe, J E Brown.   

Abstract

OBJECTIVE: The closure of a long-stay psychiatric hospital in Sydney caused the transfer of an initial 40 very long-term patients to four community residences, each with 10 beds, for a continuing process of deinstitutionalisation. Community psychiatric service support and 24-h supervision were provided. This paper describes the residents' clinical progress which was assessed over a 2-year period.
METHOD: This study employed a quasi-experimental longitudinal design. Evaluation commenced prior to discharge and continued for 2 years following community relocation using the Brief Psychiatric Rating Scale, Life Skills Profile, Social Behaviour Scale, Montgomery Asberg Depression Rating Scale and Quality Of Life measures. Readmission, demographic, case history and medication data were also collected.
RESULTS: Of the 40 patients initially transferred to the community, seven required long-term readmission to hospital (either prior to or after amalgamation) and one patient died of medical causes. Additional patients transferred from the hospital to the community following the readmissions. Three of these additional patients had achieved a 2-year community tenure during the study period and were included in the clinical evaluation. The 35 residents in total who remained in the community for 2 years, demonstrated a significant improvement in psychotic symptoms, without significant change in the level of neuroleptic medication. Importantly, the 2 years of community living resulted in a significant increase in the residents' life satisfaction. There were no statistically significant changes in residents' living skills, depressive symptoms or social behaviour problems over the 2 years, indicative of the need for supervision and community service support following deinstitutionalisation. Over the 2-year period, some 37% of the residents required temporary readmission.
CONCLUSION: This study demonstrates the clinical effectiveness of deinstitutionalisation, when planned within a mental health system with adequate community resources.

Entities:  

Mesh:

Year:  2000        PMID: 10881972     DOI: 10.1080/j.1440-1614.2000.00734.x

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  5 in total

1.  Integration is as essential as balance.

Authors:  Alan Rosen
Journal:  World Psychiatry       Date:  2002-06       Impact factor: 49.548

2.  Using the Resident Assessment Instrument-Mental Health (RAI-MH) to determine levels of care for individuals with serious mental illness.

Authors:  Carrie Gibbons; Sacha Dubois; Stephanie Ross; Barbara Parker; Kelly Morris; Therese Lim; Michel Bédard
Journal:  J Behav Health Serv Res       Date:  2007-10-26       Impact factor: 1.505

3.  Using World Health Organization Disability Assessment Schedule 2.0 in people with schizophrenia: a 4-year follow-up.

Authors:  Ruey Chen; Tsan-Hon Liou; Nae-Fang Miao; Kwang-Hwa Chang; Chia-Feng Yen; Hua-Fang Liao; Wen-Chou Chi; Kuei-Ru Chou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-04-22       Impact factor: 5.270

4.  Is psychiatric residential facility discharge possible and predictable? A multivariate analytical approach applied to a prospective study in Italy.

Authors:  G de Girolamo; V Candini; C Buizza; C Ferrari; M E Boero; G M Giobbio; N Goldschmidt; S Greppo; L Iozzino; P Maggi; A Melegari; P Pasqualetti; G Rossi
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-28       Impact factor: 4.328

5.  A systematic review of service models and evidence relating to the clinically operated community-based residential mental health rehabilitation for adults with severe and persisting mental illness in Australia.

Authors:  Stephen Parker; Gordon Hopkins; Dan Siskind; Meredith Harris; Gemma McKeon; Frances Dark; Harvey Whiteford
Journal:  BMC Psychiatry       Date:  2019-02-04       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.